Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptoms

Trial Profile

To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptoms

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Iguratimod (Primary)
  • Indications Autoimmune disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Apr 2018 Planned End Date changed from 1 May 2018 to 1 Jun 2018.
    • 10 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.
    • 15 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top